Clinical-scale lentiviral vector transduction of pbl for tcr gene therapy and potential for expression in less-differentiated cells

Journal of Immunotherapy

Volumn 31, Issue 9, 2008, Pages 830-839

  Yang, Shicheng ^a   Rosenberg, Steven A ^a   Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive immunotherapy; Gene therapy; Lentivirus; T cell receptor

Indexed keywords

GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; MICROSPHERE; PROTAMINE;

ARTICLE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CYTOTOXICITY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE; MECHANOTRANSDUCTION; MELANOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECRETION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENE; TUMOR CELL LINE;

ANTINEOPLASTIC PROTOCOLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; LENTIVIRUS; LYMPHOCYTES; MECHANOTRANSDUCTION, CELLULAR; MELANOMA; MICROSPHERES; PROTAMINES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 67650146453     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31818817c5     Document Type: Article

References (39)

1. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
2. Ikawa M, Tanaka N, Kao WW, et al. Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther. 2003;8:666-673.
3. Pfeifer A, Ikawa M, Dayn Y, et al. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA. 2002;99:2140-2145.
4. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687-696.
5. Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood. 2002;99:1165-1173.
6. Sauce D, Tonnelier N, Duperrier A, et al. Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions. J Hematother Stem Cell Res. 2002;11:929-940.
7. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003;102:497-505.
8. Chang AH, Sadelain M. The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the LTR, and the promise of lineage-restricted vectors. Mol Ther. 2007;15:445-456.
9. Wiznerowicz M, Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol. 2005;23:42-47.
10. Krogsgaard M, Davis MM. How T cells ‘see’ antigen. Nat Immunol. 2005;6:239-245.
11. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519.
12. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
13. Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005;174:4415-4423.
14. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-3295.
15. Hughes MS, Yu YY, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472.
16. Cohen CJ, Zheng Z, Bray R, et al. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol. 2005;175:5799-5808.
17. Yang S, Cohen CJ, Peng PD, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther. 2008. [Epub ahead of print].
18. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA. 2006;103:17372-17377.
19. Kohn DB. Lentiviral vectors ready for prime-time. Nat Biotechnol. 2007;25:65-66.
20. Hawley RG, Lieu FH, Fong AZ, et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
21. Johnson LA, Heemskerk B, Powell DJ Jr, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177:6548-6559.
22. Geraerts M, Willems S, Baekelandt V, et al. Comparison of lentiviral vector titration methods. BMC Biotechnol. 2006;6:34.
23. Boquest AC, Day BN, Prather RS. Flow cytometric cell cycle analysis of cultured porcine fetal fibroblast cells. Biol Reprod. 1999;60:1013-1019.
24. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714-3725.
25. Lea NC, Orr SJ, Stoeber K, et al. Commitment point during G0-->G1 that controls entry into the cell cycle. Mol Cell Biol. 2003;23:2351-2361.
26. Kimizuka F, Taguchi Y, Ohdate Y, et al. Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J Biochem. 1991;110:284-291.
27. Pollok KE, Hanenberg H, Noblitt TW, et al. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol. 1998;72:4882-4892.
28. Bouneaud C, Garcia Z, Kourilsky P, et al. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med. 2005;201:579-590.
29. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616-1626.
30. Dardalhon V, Herpers B, Noraz N, et al. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap. Gene Ther. 2001;8:190-198.
31. Barklis E, Mulligan RC, Jaenisch R. Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cells. Cell. 1986;47:391-399.
32. Colicelli J, Goff SP. Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA. J Virol. 1986;57:37-45.
33. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005;16:1241-1246.
34. Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295:868-872.
35. Ma Y, Ramezani A, Lewis R, et al. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells. 2003;21:111-117.
36. Schambach A, Galla M, Maetzig T, et al. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther. 2007;15:1167-1173.
37. Schambach A, Bohne J, Baum C, et al. Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Ther. 2006;13:641-645.
38. Abad JD, Wrzensinski C, Overwijk W, et al. T-cell receptor gene therapy of established tumors in a Murine Melanoma Model. J Immunother. 2008;31:1-6.
39. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.